Jacques Baillargeon
Psychiatry · San Antonio, TXNPI 1144212150
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 564 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 564 payments — averaging $26.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Johnson & Johnson$2K
- Validus Pharmaceuticals LLC$2K
- Otsuka America Pharmaceutical, Inc.$1K
- plus $5K from 20 others
What the payments were for
- Food & beverage$14,946100%
- Education$440%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 98 | $2,084 |
| Teva Pharmaceuticals USA, Inc. | 62 | $2,069 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $1,678 |
| Johnson & Johnson | 61 | $1,624 |
| Validus Pharmaceuticals LLC | 24 | $1,534 |
| Otsuka America Pharmaceutical, Inc. | 61 | $1,268 |
| Vanda Pharmaceuticals Inc. | 30 | $738 |
| Almatica Pharma LLC | 41 | $733 |
| E.r. Squibb & Sons, L.L.C. | 14 | $553 |
| Axsome Therapeutics, Inc. | 19 | $511 |
| Lundbeck LLC | 28 | $507 |
| Bausch Health US, LLC | 26 | $403 |
| Eisai Inc. | 2 | $239 |
| Neurocrine Biosciences, Inc. | 11 | $206 |
| Alkermes, Inc. | 4 | $163 |
| Supernus Pharmaceuticals, Inc. | 3 | $145 |
| Idorsia Pharmaceuticals US Inc | 2 | $138 |
| Avanir Pharmaceuticals, Inc. | 6 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $62 |
| Merck | 3 | $54 |
| Arbor Pharmaceuticals, Inc. | 3 | $47 |
| Noven Therapeutics, LLC | 2 | $43 |
| Shire North American Group Inc | 2 | $43 |
| Indivior Inc. | 2 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Equetro$1,167
- VRAYLAR$749
- CAPLYTA$625
- Austedo XR$617
- SPRAVATO$458
- LYBALVI$400
- COBENFY$379
- Fanapt$368
- AUSTEDO$357
- REXULTI$247
- UZEDY$240
- Dayvigo$239
- INVEGA SUSTENNA$150
- INVEGA TRINZA$150
- SUNOSI$125
- QUVIVIQ$124
- QELBREE$112
- Auvelity$104
- ABILIFY MAINTENA$100
How this compares
$14,990 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 21 | $49,478 |
| RexultiBrexpiprazole | 13 | $21,357 |
| CaplytaLumateperone Tosylate | 13 | $21,229 |
| BelsomraSuvorexant | 12 | $5,367 |
| Aripiprazole | 112 | $4,944 |
| Divalproex Sodium ErDivalproex Sodium | 106 | $4,718 |
| Paliperidone ErPaliperidone | 12 | $3,963 |
| Alprazolam | 309 | $2,479 |
| Bupropion XlBupropion Hcl | 104 | $2,255 |
| Clonazepam | 205 | $1,925 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 21 | $1,600 |
| Quetiapine Fumarate | 54 | $1,415 |
| Ziprasidone Hcl | 22 | $1,345 |
| Methylphenidate ErMethylphenidate Hcl | 13 | $1,270 |
| Carbamazepine | 35 | $1,211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,268 | $70,83534 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,678 | $21,22913 claims |
| MerckBelsomra | $54 | $5,36712 claims |
| Almatica Pharma LLCSertraline Hcl | $733 | $1,054142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in San Antonio
- Thomas WeissSan Antonio$744K
- Nathan JohnstonSan Antonio$435K
- Damaso OlivaSan Antonio$170K
- Edmund WilliamsSan Antonio$142K
- Jair SoaresSan Antonio$69K
- James RedmondSan Antonio$42K
- Rakesh JainLake Jackson$7.2M
- Arvinder Pal WaliaAustin$2.5M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.